<DOC>
	<DOCNO>NCT01977430</DOCNO>
	<brief_summary>Introduction : Chronic kidney disease characterize progressive deterioration renal function . At end progression , complication occur ( overhydration , electrolyte imbalance retention uremic toxin ) , percentage patient require renal replacement therapy ( haemodialysis ) . When start haemodialysis , patient hold residual renal function ( RRF ) lose time . To preserve RRF , patient treat diuretic loops / thiazide diuretic . The effect treatment lose renal function worsens . In context , study explore use effectiveness diuretic patient haemodialysis 2 . Objectives Hypothesis : Hypothesis : The treatment furosemide hydrochlorothiazide haemodialysis patient RRF could : - To decrease weight gain haemodialysis session . - To increase urine volume . - To decrease ultrafiltration haemodialysis session ( long interdialytic interval ) Main Objective : To ass effect combine hydrochlorothiazide-furosemide therapy gain weight haemodialysis session patient RRF Secondary Objective : To ass effect combine hydrochlorothiazide-furosemide therapy dialytic , clinical analytical variable use antihypertensive treatment 3 . Methodology : Randomized open clinical trial compare effectiveness administration diuretic haemodialysis patient residual renal function single centre . The population study patient chronic renal disease haemodialysis therapy preserve residual renal function ( 200ml daily urine ) . It simple randomization , asses effect combine hydrochlorothiazide-furosemide therapy After 15 day washout without diuretic treatment , patient randomize receive receive combine diuretic treatment 1 month . After 1 month washout , patient receive treatment accord cross trial .</brief_summary>
	<brief_title>Clinical Trial Compare Effectiveness Diuretics Hemodialysis Patients With Residual Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Over 18 year Chronic kidney disease , stage 5 Chronic Kidney Disease , haemodialysis Renal residual function preserve ( equal 200 ml daily urine ) Minimum 3 month haemodialysis wish participate study Exclusion criterion : Less 4 millequivalent potassium plasma interdialytic session require potassium intradialytic treatment . Less 1 Kg gain weight long interdialytic interval . Adverse effect treatment past . To refusal participate study . Pregnancy lactation period . Contraindication use diuretic therapy , accord pharmacological profile .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Residual renal function</keyword>
	<keyword>Combined thiazide-furosemide therapy</keyword>
	<keyword>Haemodialysis</keyword>
</DOC>